Literature DB >> 8507219

Levels of synovial fluid interleukin-1 receptor antagonist in rheumatoid arthritis and other arthropathies. Potential contribution from synovial fluid neutrophils.

M Malyak1, R E Swaney, W P Arend.   

Abstract

OBJECTIVE: To measure synovial fluid (SF) levels of interleukin-1 receptor antagonist (IL-1ra) and to determine the capacity of SF neutrophils (PMN) to synthesize and release IL-1ra.
METHODS: A sensitive and specific enzyme-linked immunosorbent assay was used to measure SF IL-1ra protein concentrations and IL-1ra production by isolated SF PMN:
RESULTS: SF IL-1ra levels were elevated in 13 of 16 samples from patients with rheumatoid arthritis (RA) (mean 17.1 ng/ml), in 6 of 18 samples from patients with infectious or inflammatory, non-RA arthropathies (mean 10.6 ng/ml), and in none of 11 noninflammatory SF samples. SF IL-1ra levels correlated with SF PMN concentrations (r = 0.680, P < 0.00001). Isolated SF PMN contained preexisting IL-1ra protein in the absence of messenger RNA (mRNA). In addition, both lipopolysaccharide and granulocyte-macrophage colony-stimulating factor induced modest increases in IL-1ra mRNA by cultured SF-PMN.
CONCLUSION: IL-1ra levels are increased in > 80% of RA SF samples. SF PMN produce IL-1ra, possibly contributing to the levels of IL-1ra present within the SF.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8507219     DOI: 10.1002/art.1780360607

Source DB:  PubMed          Journal:  Arthritis Rheum        ISSN: 0004-3591


  15 in total

1.  Ex vivo interleukin 1 receptor antagonist production on lipopolysaccharide stimulation is associated with rheumatoid arthritis and with joint damage.

Authors:  J K de Vries-Bouwstra; Y P M Goekoop-Ruiterman; J Wesoly; H J Hulsmans; A J M de Craen; F C Breedveld; B A C Dijkmans; C F Allaart; T W J Huizinga
Journal:  Ann Rheum Dis       Date:  2007-01-12       Impact factor: 19.103

2.  Alpha-1-antitrypsin therapy ameliorates acute colitis and chronic murine ileitis.

Authors:  Colm B Collins; Carol M Aherne; Stefan F Ehrentraut; Mark E Gerich; Eóin N McNamee; Martine C McManus; Matthew D P Lebsack; Paul Jedlicka; Tania Azam; Edwin F de Zoeten; Charles A Dinarello; Jesús Rivera-Nieves
Journal:  Inflamm Bowel Dis       Date:  2013-08       Impact factor: 5.325

Review 3.  Cytokines in rheumatoid arthritis. Potential targets for pharmacological intervention.

Authors:  Z Szekanecz; A E Koch; S L Kunkel; R M Strieter
Journal:  Drugs Aging       Date:  1998-05       Impact factor: 3.923

4.  The role of tumour necrosis factor-alpha and IL-1 in polymorphonuclear leucocyte and T lymphocyte recruitment to joint inflammation in adjuvant arthritis.

Authors:  A C Issekutz; A Meager; I Otterness; T B Issekutz
Journal:  Clin Exp Immunol       Date:  1994-07       Impact factor: 4.330

Review 5.  Cytokines in rheumatoid arthritis.

Authors:  F A Houssiau
Journal:  Clin Rheumatol       Date:  1995-09       Impact factor: 2.980

Review 6.  Treatment of rheumatoid arthritis with IL-1 inhibitors.

Authors:  C Gabay; W P Arend
Journal:  Springer Semin Immunopathol       Date:  1998

7.  Autoantibodies against interleukin 1alpha in rheumatoid arthritis: association with long term radiographic outcome.

Authors:  N A Graudal; M Svenson; U Tarp; P Garred; A-G Jurik; K Bendtzen
Journal:  Ann Rheum Dis       Date:  2002-07       Impact factor: 19.103

8.  Interleukin-1 receptor antagonist production in cultured synovial cells from patients with rheumatoid arthritis and osteoarthritis.

Authors:  Y Fujikawa; M Shingu; T Torisu; S Masumi
Journal:  Ann Rheum Dis       Date:  1995-04       Impact factor: 19.103

9.  Difference in gene expression of macrophage between normal spleen and portal hypertensive spleen identified by cDNA microarray.

Authors:  Feng Yan; Xiao-Min Wang
Journal:  World J Gastroenterol       Date:  2007-06-28       Impact factor: 5.742

10.  Synovial fluid cytokine concentrations as possible prognostic indicators in the ACL-deficient knee.

Authors:  M L Cameron; F H Fu; H H Paessler; M Schneider; C H Evans
Journal:  Knee Surg Sports Traumatol Arthrosc       Date:  1994       Impact factor: 4.342

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.